Flag of the European Union EU Clinical Trials Register Help

Clinical trials for prostate cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    815 result(s) found for: prostate cancer. Displaying page 4 of 41.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2008-004351-29 Sponsor Protocol Number: 2008-02-IMP-5 Start Date*: 2008-12-18
    Sponsor Name:HEXAL AG
    Full Title: OPEN LABEL, MULTICENTER STUDY ON PHARMACOKINETICS, PHARMACODYNAMICS, EFFICACY AND SAFETY OF GOSERELIN 10.8 mg IMPLANT HEXAL IN PATIENTS WITH ADVANCED HORMONE DEPENDENT PROSTATE CANCER
    Medical condition: Palliative treatment of advanced hormone dependent prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-008301-22 Sponsor Protocol Number: 1661/08 Start Date*: 2010-03-05
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: PHASE II CLINICAL STUDY OF THE DIAGNOSTIC EFFICACY OF [18F]FLUOROETHYILCHOLINE ([18F]FECh) IN PATIENTS WITH PROSTATE CANCER
    Medical condition: PROSTATE CANCER
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036908 Prostatic neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-003185-26 Sponsor Protocol Number: 2016-NUK-01 Start Date*: 2016-10-20
    Sponsor Name:Aarhus University Hospital
    Full Title: Qualification of 82Rb PET for measurement of tumor perfusion. Uptake in primary prostate cancer vs healthy prostate
    Medical condition: Cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10036910 Prostate cancer NOS LLT
    19.0 100000004848 10065410 Combined positron emission tomogram and computerized tomogram LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-004846-39 Sponsor Protocol Number: N-20200025 Start Date*: 2023-04-26
    Sponsor Name:Aalborg University Hospital
    Full Title: 68Ga-PSMA PET/CT vs. 18F-PSMA PET/CT for the diagnosis of metastases in newly diagnosed high-risk prostate cancer patients undergoing radical prostatectomy
    Medical condition: Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036910 Prostate cancer NOS LLT
    21.1 100000004848 10065410 Combined positron emission tomogram and computerized tomogram LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-007072-42 Sponsor Protocol Number: 20599 Start Date*: 2008-07-08
    Sponsor Name:University Medical Center Utrecht
    Full Title: Double-blind placebo-controlled randomized study to determine the effectiveness of magnesium oxide to reduce the prostate motion.
    Medical condition: Prostate cancer patients who are being treated with external beam radiotherapy using fiducial marker-based position verification.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001506-96 Sponsor Protocol Number: TCD12128 Start Date*: 2012-03-27
    Sponsor Name:sanofi-aventis recherche et développement
    Full Title: A Phase I/II Study of Cabazitaxel Combined with Abiraterone Acetate and Prednisone in Patients with Metastatic Castrate-Resistant Prostate Cancer (CRPC) whose Disease has Progressed after Docetaxe...
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-005964-24 Sponsor Protocol Number: CRO-06-78 / DSC/06/LEU15/01 Start Date*: 2007-04-03
    Sponsor Name:Italfarmaco S.p.A.
    Full Title: Pharmacokinetics, pharmacodynamics and safety of a new Leuprolide acetate 22.5 mg depot formulation, when given as palliative treatment to prostate cancer patients
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10007113 Cancer of prostate LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003183-68 Sponsor Protocol Number: PSMA-RGS Start Date*: 2020-12-10
    Sponsor Name:OSPEDALE SAN RAFFAELE
    Full Title: The Role of Imaging Guided Surgery to Improve the Detection of LymphNode metastases in Prostate Cancer Patients Treated with Radical Prostatectomy and Extended Pelvic Lymph Node Dissection
    Medical condition: Patients with prostate cancer (PCa) who are candidate to undergo surgical treatment with robot-assisted radical prostatectomy with a risk of lymph nodal invasion > 5% according to preoperative data
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10026389 Malignant neoplasm of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-000860-32 Sponsor Protocol Number: UMCN-AKF-14.17 Start Date*: 2015-04-28
    Sponsor Name:Radboud University Medical Center
    Full Title: Personalizing enzalutamide (Xtandi®) therapy by understanding the relation between the decrease in the expression profile of a panel of preselected microRNAs, tumor related mRNAs and treatment resp...
    Medical condition: Metastatic Castration Resistant Prostate Cancer (mCRPC)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036909 Prostate cancer metastatic PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062904 Hormone-refractory prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003525-16 Sponsor Protocol Number: DOCRTPC Start Date*: 2007-05-02
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: Neoadjuvant chemotherapy with weekly docetaxel followed from concomitant docetaxel-RT in patients with high risk locally advanced prostate cancer
    Medical condition: high risk locally advanced prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022037-29 Sponsor Protocol Number: AFU-GETUG 20/0310 Start Date*: 2011-01-31
    Sponsor Name:FNCLCC (Fédération Nationale des Centres de Lutte Contre le Cancer)
    Full Title: Phase III randomised trial to evaluate the benefit of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients with high risk of r...
    Medical condition: PROSTATIC ADENOCARCINOMA WITH HIGH RISK OF RECURRENCE.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10060862 Prostate cancer LLT
    Population Age: Gender: Male
    Trial protocol: FR (Trial now transitioned) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-004419-69 Sponsor Protocol Number: P070129 Start Date*: 2008-04-02
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Impact de la TEP-TDM à la Fluorométhylcholine-(18F) sur la prise en charge de la récidive biologique occulte du cancer de la prostate. Etude multicentrique nationale de phase III. (ICHOROPRO)
    Medical condition: Récidive biologique occulte du cancer de la prostate
    Disease: Version SOC Term Classification Code Term Level
    8.1 10060862 prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-009114-40 Sponsor Protocol Number: 2009/01 Start Date*: 2009-03-16
    Sponsor Name:Hopital Foch
    Full Title: Impact de la technique anesthésique et analgésique sur le risque de récidive biologique de cancer de la prostate
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-001685-15 Sponsor Protocol Number: ANTI-3-18F-FACBC Start Date*: 2012-05-22
    Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
    Full Title: ANTI-3-18F-FACBC IN COMPARISON TO 11C-CHOLINE PET/CT IN THE EVALUATION OF PATIENTS WITH SUSPECT PROSTATE CANCER RELAPSE
    Medical condition:  Patients with prostate cancer treated with radical prostatectomy or radiotherapy presenting with suspect progression(rising PSA) of local or distant (lymphnodes or bones) already scheduled for a ...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036908 Prostatic neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005232-33 Sponsor Protocol Number: FE200486 CS30 Start Date*: 2009-04-15
    Sponsor Name:Ferring Pharmaceuticals A/S
    Full Title: A randomised, parallel arm, open-label trial comparing degarelix with goserelin plus anti-androgen flare protection (bicalutamide), in terms of prostate size reduction in prostate cancer patients o...
    Medical condition: Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: NL (Completed) DE (Completed) FR (Completed) ES (Completed) GB (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2007-001703-38 Sponsor Protocol Number: ARI109924 Start Date*: 2007-09-25
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Randomised, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Dutasteride (AVODART™) 0.5 mg in Extending the Time to PSA Doubling in Men with Prostate Cancer and Biochem...
    Medical condition: Clinically localised prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FI (Completed) SE (Completed) FR (Completed) ES (Completed) LT (Prematurely Ended) LV (Prematurely Ended) NL (Completed) GB (Completed) EE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-006595-38 Sponsor Protocol Number: SU/2006/2424 Start Date*: 2007-08-03
    Sponsor Name:University Hospitals Bristol NHS Foundation Trust
    Full Title: A Phase II, Open-Label, Single-Arm Study to Assess the Efficacy and Safety of Decapeptyl® SR (3 mg and 11.25 mg formulations) when administered by subcutaneous injection
    Medical condition: Enrolled patients will be those who have a diagnosis of prostate cancer and for whom medical castration by means of Luteinising Hormone Releasing Hormone analogue (LHRHa) injection is indicated.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10060862 Prostate cancer LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005165-11 Sponsor Protocol Number: GETUG 16/0504 Start Date*: 2006-06-16
    Sponsor Name:Fédération Nationale des Centres de Lutte Contre le Cancer
    Full Title: Etude randomisée multicentrique comparant l'efficacité d'une hormonothérapie courte par Zoladex® concomitante à une radiothérapie versus une radiothérapie exclusive dans le traitement de rattrapage...
    Medical condition: Avec 40 000 nouveaux cas par an en France, le cancer de la prostate est le second cancer pour l’ensemble de la population française et le premier chez l’homme. L'hormonothérapie est le traitement ...
    Disease: Version SOC Term Classification Code Term Level
    V.8 10060862 LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-000566-38 Sponsor Protocol Number: GETUG-AFU_23_/_UC-0160/1202 Start Date*: 2014-07-23
    Sponsor Name:UNICANCER
    Full Title: A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse
    Medical condition: localized prostate cancer with high-risk features of relapse
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Trial now transitioned) ES (Ongoing) IT (Prematurely Ended) BE (Trial now transitioned) DE (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-004628-21 Sponsor Protocol Number: SAMDOCET Start Date*: 2008-12-02
    Sponsor Name:AZIENDA OSPEDALIERA PISANA
    Full Title: A multicenter phase III randomized study of 153Sm-EDTMP and Docetaxel + Prednisone versus Docetaxel + Prednisone in Taxane-naive patients with metastatic hormone-refractory prostate cancer.
    Medical condition: Taxane-naive patients with metastatic hormone-refractory prostate cancer.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036908 Prostatic neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Ongoing) FR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jun 05 22:36:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA